A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Inclusion Criteria:

- ESRD with a history of sensitizing events

- United network for organ sharing (UNOS) listed for a deceased donor kidney
transplantation

- Estimated high likelihood of receiving an offer in the coming 12-18 months from
screening as evidenced by: present on at least one match run for a deceased donor
kidney during the past year, or calculated panel reactive antibody (cPRA) greater than
or equal to (≥) 98 percent (based on revisions to allocation policy introduced in
2014)

- Female participants of childbearing potential: agreement to remain abstinent or use
two adequate methods of contraception during the treatment period and for at least 18
months after the last dose of study drug

- Male participants: agreement to remain abstinent or use contraceptive measures and
agreement to refrain from donating sperm during the treatment period and for at least
12 months after the last dose of study drug

Exclusion Criteria:

- Incomplete recovery from recent major surgery or less than (<) 12 weeks since major
surgery prior to baseline and participants planned surgery within 24 weeks of baseline
except for kidney transplantation

- Pregnant or lactating women

- Positive serum human chorionic gonadotropin (hCG) measured at screening unless
considered not clinically significant based on best medical judgement and if
reassessment after ≥48 hours shows a less than a 2-fold rise from previous level

- Primary or secondary immunodeficiency disease

- Seropositivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody
(HBcAb) or seropositivity for Hepatitis C

- History of active or latent tuberculosis (TB) or suspicion of active TB

- Known active infection of any kind or any major episode of infection requiring
hospitalization or treatment with IV anti-infective agents within 4 weeks of baseline
or completion of oral anti-infective agents within 2 weeks prior to baseline

- Currently active alcohol or drug abuse or history of alcohol or drug abuse

- Participants with a history of prior kidney transplantation(s) after 6 participants
with prior kidney transplants will be enrolled in the study

- Participants on peritoneal dialysis with a history of peritoneal infection at any time
during the 12 weeks from prior to screening

- Participants on peritoneal dialysis with a positive culture or high cell count numbers
on peritoneal fluid indicative of confirmed or suspected infection at the time of
screening.

- Participants for synchronous organ transplant

- Recipients of any live attenuated vaccine(s) within 1 month of the screening visit

- Abnormal screening laboratory results

- Participants with a history of major cardiovascular or pulmonary disease

- Use of investigational agents within 12 weeks or five half-lives of randomization

- Use of an anti-CD20 therapy within the past 12 months

- Known contraindications to obinutuzumab

- History of severe allergic or anaphylactic reactions to monoclonal antibodies or
components of obinutuzumab infusion